These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin. Jacobson IM, Marcellin P, Zeuzem S, Sulkowski MS, Esteban R, Poordad F, Bruno S, Burroughs MH, Pedicone LD, Boparai N, Deng W, DiNubile MJ, Gottesdiener KM, Brass CA, Albrecht JK, Bronowicki JP. Hepatology; 2012 Aug; 56(2):567-75. PubMed ID: 22619063 [Abstract] [Full Text] [Related]
16. Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials. Sitole M, Silva M, Spooner L, Comee MK, Malloy M. Clin Ther; 2013 Feb; 35(2):190-7. PubMed ID: 23369368 [Abstract] [Full Text] [Related]
17. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, Moroz L, Craxi A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Scott J, Sinha R, Beumont-Mauviel M. Lancet; 2014 Aug 02; 384(9941):403-13. PubMed ID: 24907225 [Abstract] [Full Text] [Related]